XNAS · Healthcare · Diagnostics & Research
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
Nasdaq warned ENDRA's stockholders' equity was below the **$2.5 million** minimum, underscoring severe balance-sheet stress. With no revenue and no earnings catalyst, the diagnostics story remains highly speculative and execution-risk heavy.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-17 | Q2 2026 | -0.84 | 0.06 | +107.14% | $0 | ✅ Beat | +6.71% | +1.56% | — |
| 2026-05-18 | Q1 2026 | -1.23 | -1.09 | +11.38% | $0 | ✅ Beat | -0.99% | -3.88% | -7.39% |
| 2026-03-31 |
| Q4 2025 |
| -1.23 |
| -3.25 |
| -164.23% |
| $0 |
| ❌ Miss |
| +1.51% |
| +14.84% |
| +4.73% |
| 2025-11-17 | Q3 2025 | -1.95 | -2.10 | -7.69% | $0 | ❌ Miss | — | — | — |
| 2025-03-31 | Q4 2024 | — | -7.35 | — | $0 | — | -4.39% | +6.83% | +46.59% |
| 2024-11-15 | Q3 2024 | -70.00 | -333.90 | -377.00% | $0 | ❌ Miss | -8.15% | +12.11% | -3.30% |
| 2024-08-14 | Q2 2024 | -122.50 | -140.00 | -14.29% | $0 | ❌ Miss | -5.63% | -83.78% | -91.65% |
| 2024-05-14 | Q1 2024 | -472.50 | -455.00 | +3.70% | $0 | ✅ Beat | +0.28% | +4.56% | -65.14% |
Showing last 8 quarters.